TNFα repression by the phosphodiester-inhibitor pentoxifylline and by treatment with TNFα antibody alleviates TNFα-induced liver damage in mice and improves the short-term survival of ALD patients, respectively, but increases the risk for infections in ALD patients. Here, TNF is linked to infection.